Abstract
COVID-19 continues to have significant impact globally. Especially the lockdown periods that started in March and October 2020 impacted all areas of daily business, including HTA bodies and their capacity to process HTA submissions. This analysis aims to quantify and investigate to what extent single drug assessments (SDAs) were negatively impacted by COVID-19 looking at publication volume as well as any changes in HTA decisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
